Elena Sebokova

Summary

Affiliation: F. Hoffmann-La Roche Ltd

Publications

  1. ncbi Dipeptidyl peptidase IV inhibitors: the next generation of new promising therapies for the management of type 2 diabetes
    Elena Sebokova
    F Hoffmann La Roche Ltd, Vascular and Metabolic Diseases, Grenzacherstrasse 124, 4070 Basel, Switzerland
    Curr Top Med Chem 7:547-55. 2007
  2. ncbi Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor ?/? agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome
    Barbara C Hansen
    Department of Internal Medicine and Pediatrics, University of South Florida, Tampa, FL, USA
    Cardiovasc Diabetol 10:7. 2011
  3. ncbi Taspoglutide, an analog of human glucagon-like Peptide-1 with enhanced stability and in vivo potency
    Elena Sebokova
    F Hoffmann La Roche AG, PRDM, Building 68 310 Grenzacherstrasse 124, CH 4070 Basel, Switzerland
    Endocrinology 151:2474-82. 2010
  4. ncbi Taspoglutide, a novel human once-weekly analogue of glucagon-like peptide-1, improves glucose homeostasis and body weight in the Zucker diabetic fatty rat
    E Sebokova
    F Hoffmann La Roche AG, Basel, Switzerland
    Diabetes Obes Metab 12:674-82. 2010
  5. ncbi Aryl- and heteroaryl-substituted aminobenzo[a]quinolizines as dipeptidyl peptidase IV inhibitors
    Markus Boehringer
    F Hoffmann La Roche Ltd, Pharma Research, CH 4070 Basel, Switzerland
    Bioorg Med Chem Lett 20:1106-8. 2010
  6. ncbi Discovery of carmegliptin: a potent and long-acting dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
    Patrizio Mattei
    F Hoffmann La Roche Ltd, Pharma Research, CH 4070 Basel, Switzerland
    Bioorg Med Chem Lett 20:1109-13. 2010

Collaborators

  • Bernd Kuhn
  • Patrizio Mattei
  • Haiyan Wang
  • Daniel Hunziker
  • Barbara C Hansen
  • Markus Boehringer
  • Jacques Mizrahi
  • Agnes Benardeau
  • Xenia T Tigno
  • Markus Meyer
  • Bernd M Loeffler
  • Hans Peter Wessel
  • Michael Hennig
  • Holger Fischer
  • Urs Sprecher
  • Joerg Huwyler
  • Thomas Luebbers
  • Robert Narquizian

Detail Information

Publications6

  1. ncbi Dipeptidyl peptidase IV inhibitors: the next generation of new promising therapies for the management of type 2 diabetes
    Elena Sebokova
    F Hoffmann La Roche Ltd, Vascular and Metabolic Diseases, Grenzacherstrasse 124, 4070 Basel, Switzerland
    Curr Top Med Chem 7:547-55. 2007
    ..The present article focuses on the preclinical and clinical data of DPP-IV inhibitors that make it unique therapeutic agents representing the next generation of antidiabetes drugs...
  2. ncbi Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor ?/? agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome
    Barbara C Hansen
    Department of Internal Medicine and Pediatrics, University of South Florida, Tampa, FL, USA
    Cardiovasc Diabetol 10:7. 2011
    ....
  3. ncbi Taspoglutide, an analog of human glucagon-like Peptide-1 with enhanced stability and in vivo potency
    Elena Sebokova
    F Hoffmann La Roche AG, PRDM, Building 68 310 Grenzacherstrasse 124, CH 4070 Basel, Switzerland
    Endocrinology 151:2474-82. 2010
    ..Excellent stability and potency with substantial glucoincretin effects position taspoglutide as a promising new agent for treatment of type 2 diabetes...
  4. ncbi Taspoglutide, a novel human once-weekly analogue of glucagon-like peptide-1, improves glucose homeostasis and body weight in the Zucker diabetic fatty rat
    E Sebokova
    F Hoffmann La Roche AG, Basel, Switzerland
    Diabetes Obes Metab 12:674-82. 2010
    ..We investigated the effects of a novel, long-acting human GLP-1 analogue, taspoglutide, in the Zucker diabetic fatty (ZDF) rat, an animal model of type 2 diabetes...
  5. ncbi Aryl- and heteroaryl-substituted aminobenzo[a]quinolizines as dipeptidyl peptidase IV inhibitors
    Markus Boehringer
    F Hoffmann La Roche Ltd, Pharma Research, CH 4070 Basel, Switzerland
    Bioorg Med Chem Lett 20:1106-8. 2010
    ..However, (S,S,S)-2i, bearing a more hydrophilic 5-methyl-pyridin-2-yl residue as substituent for the S1 pocket, displays excellent in vivo activity and superior drug-like properties...
  6. ncbi Discovery of carmegliptin: a potent and long-acting dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
    Patrizio Mattei
    F Hoffmann La Roche Ltd, Pharma Research, CH 4070 Basel, Switzerland
    Bioorg Med Chem Lett 20:1109-13. 2010
    ..One representative thereof, carmegliptin (8p), was chosen for clinical development. Its X-ray structure in complex with the enzyme and early efficacy data in animal models of type 2 diabetes are also presented...